ASML Faces a Fork in the Road as July Earnings Collide With China Export Uncertainty

ASML shares slip 7.5% from all-time high as record EUV backlog clashes with US legislative risk to China sales; Q2 earnings on July 15 pivotal.

The Dutch chip-equipment giant has spent the past week buffeted by conflicting currents. After touching an all-time high of €1,710 on June 22, the stock slid roughly 7.5% to close Friday at €1,582. That still leaves it up nearly 60% for the year, but the pullback masks a deeper tension: a record wave of EUV orders is running headlong into a US legislative threat that could sever ASML’s last remaining sales channel to China.

Investors are now marking their calendars for July 15, when the company reports second-quarter results. The guidance calls for net sales between €8.4 billion and €9.0 billion and a gross margin of 51%–52%, with consensus earnings per share around €8.03. Yet the numbers alone will not settle the debate. The real flashpoint is what management reveals about the order book for 2027 — and whether any fresh signals emerge on the MATCH Act’s trajectory.

The bull case: Memory boom and High-NA become twin engines

Demand for ASML’s extreme ultraviolet lithography machines has rarely been stronger. The company lifted its 2026 revenue forecast to €36–€40 billion, and CEO Christophe Fouquet stated bluntly that chip demand outstrips supply. In the first quarter of 2026, net sales climbed 13% to €8.8 billion and net profit rose 17% to €2.8 billion.

Memory is emerging as a second structural growth pillar. South Korea accounted for 45% of Q1 revenue, with more than half of quarterly shipments going into memory production. SK Hynix and Samsung are snapping up EUV systems to feed demand for high-bandwidth memory and advanced DRAM for AI data centers. Micron Technology provided a fresh tailwind last week when it reported quarterly revenue of $41.46 billion — more than quadruple the year-ago figure. CEO Sanjay Mehrotra said tight market conditions are likely to persist beyond calendar 2027, suggesting equipment orders will not let up.

At the same time, ASML is ramping High-NA EUV. It plans to ship ten High-NA scanners this year. Intel is using them for its 14A node, and SK Hynix is expected to take two units for memory applications. CFO confirmations indicate ASML will deliver around 60 low-NA EUV systems in 2026 — 25% more than in 2025 — with capacity for 80 in 2027.

The order backlog backs up that visibility. ASML ended 2025 with a €38.8 billion backlog, and Q4 bookings hit a record €13.2 billion, of which €7.4 billion came from EUV orders. That locks in revenue well into 2027.

The bear case: MATCH Act and the fragility of AI capex

The most immediate downside risk is the MATCH Act, a bipartisan US bill that would extend export controls to all immersion DUV machines — precisely the category ASML can still sell to China. China accounts for 19% of net system sales, representing roughly one-fifth of expected 2026 revenue. The bill has cleared a committee but not yet the full Congress. Dutch Trade Minister Sjoerd Sjoerdsma traveled to Washington to lobby against it, meeting with US Commerce Secretary Howard Lutnick.

Tensions escalated in mid-June when US authorities alleged that a high-value ASML machine may have been shipped to China in violation of existing export rules. ASML denied the claim. Were the MATCH Act to pass in its current form, analysts estimate a revenue hit of around 5%, though the impact could be larger if enforcement widens.

Adding to the uncertainty: ASML stopped disclosing order figures for the first quarter of 2026 — a closely watched leading indicator. Investors now must wait until July 15 for a fresh look at booking trends. Other open questions include a slow start to immersion sales and doubts about the company’s ambitious 2027 delivery targets.

A broader pullback in AI capital expenditure — unlikely in the near term but not impossible — would compress new orders and put pressure on ASML’s elevated valuation.

A new competitive front — or a false alarm?

Beyond geopolitics, a startup called xLight has captured attention. Backed by $150 million from the US Commerce Department and NIST, and founded by former Intel CEO Pat Gelsinger, xLight is developing an alternative EUV light source based on free-electron lasers. A prototype is slated for 2028 at the Albany NanoTech Complex in New York. But xLight is not positioning itself as a rival — its goal is to sell the technology to ASML. Fouquet confirmed that the two companies are already collaborating technically. Meanwhile, xLight is negotiating a further $350 million funding round led by Boardman Bay Capital Management and Bain Capital.

A more openly competitive startup is Substrate, supported by Peter Thiel, which is pursuing its own EUV alternative.

What July 15 will reveal

Technically, ASML’s 50-day moving average sits at €1,402 — roughly 12% below the current price. The relative strength index at 54.8 leaves room for movement in either direction. Of 44 analysts covering the stock, the average rating is “Strong Buy.” Bank of America recently raised its price target to $2,345, while Wells Fargo lifted its target to $2,200 from $1,750. Both keep buy ratings.

But the key catalysts are not on any spreadsheet. The July 15 report will be dissected for three things: order trends under the new non-disclosure policy, any update on China exposure, and progress on High-NA deliveries. Bank of America expects the 2027 order book to be already full at that point, potentially shifting the conversation to 2028 earnings potential.

Land the quarter at the high end of guidance, reassure on China, and the retreat from the all-time high may look like a mere consolidation. Let the MATCH Act advance through Congress or deliver underwhelming sales, and the gap between ASML’s ambitious valuation and a tightening revenue profile will snap into focus. July 15 is more than a routine earnings date. It is the first genuine test of whether ASML’s growth story can withstand the regulatory headwinds piling up around it.